Poster: CLL-390 Persistence and Time to Next Treatment With Ibrutinib Treatment in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Including Patients at High Risk for Atrial Fibrillation or Stroke: A Real-World Study

This study demonstrates the real-world use of ibrutinib in patients at high baseline risk of AF/AF-related events and highlights that baseline AF-related risk does not adversely impact TTD and TTNT associated with ibrutinib use in CLL/SLL patients. In addition, TTNT was significantly longer for patients treated with ibrutinib-based regimens than other regimens.